Lexaria Updates Business Development

About this update from Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA. "Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements. Not a week goes by without discussion with one or more potential partners." While new corporate relationships require time to identify areas of common interest and capabilities, including but not limited to technologic compatibility, we also continue to advance our pre-existing corporate relationships. While timelines and closure rates are impossible to predict, Lexaria remains optimistic about its prospects. Of note, most of Lexaria's business discussions are related to the GLP-1 sector and its many applications. Within the GLP-1 sector, Lexaria detected a notable shift in this year's BIO conference to a focus on drug safety and adverse event profiles, given the reality that certain drugs currently under development are approaching practical maximums of weight-loss efficacy. Both in public presentations as well as in our one-on-one meetings, a growing number of pharmaceutical companies are confirming that their focus has shifted towards finding a better balance between weight-loss efficacy, tolerability and safety. The idea that GLP-1 drugs can work effectively at the same time as minimizing unpleasant adverse events is consistent with both Lexaria's mission, and the capabilities of our DehydraTECHTM technology. In addition, Lexaria is pleased to report that interest in DehydraTECH technology is expanding once again outside of the GLP-1 industry. Lexaria has recently received renewed incoming corporate interest in the DehydraTECH-CBD and DehydraTECH-nicotine sectors where the Company has conducted extensive previous R&D validating the efficacy of the DehydraTECH technology. Additional business development information will...

View stock analysis, news, and events for Lexaria Bioscience Corp.